Aspergillus fumigatus tricuspid native valve endocarditis in a non-intravenous drug user.
Invasive aspergillosis is an emerging infection mainly affecting immunocompromised patients. This report details a case of Aspergillus fumigatus tricuspid native valve endocarditis complicated by recurrent septic pulmonary emboli in a young, non-intravenous drug user. He was treated by surgical resection of the posterior leaflet of the tricuspid valve and the vegetations, as well as by valvuloplasty, which was followed by a combination of liposomal amphotericin B and voriconazole as acute-phase therapy and voriconazole alone as suppression therapy.
Antonios
A
Vassiloyanakopoulos
Department of Medicine, Tufts University School of Medicine, Boston, MA, USA.|Alfa Institute of Biomedical Sciences (AIBS), Athens, Greece.
Matthew E
ME
Falagas
Maria
M
Allamani
Alfa Institute of Biomedical Sciences (AIBS), Athens, Greece.
Argyris
A
Michalopoulos
D000328:Adult; D000666:Amphotericin B / Q000494:pharmacology / Q000627:therapeutic use; D000935:Antifungal Agents / Q000494:pharmacology / Q000627:therapeutic use; D001228:Aspergillosis / Q000150:complications / Q000188:drug therapy / Q000382:microbiology* / Q000601:surgery; D001232:Aspergillus fumigatus / Q000302:isolation & purification*; D003131:Combined Modality Therapy; D004696:Endocarditis / Q000150:complications* / Q000188:drug therapy / Q000382:microbiology* / Q000601:surgery; D006349:Heart Valve Diseases / Q000150:complications / Q000188:drug therapy / Q000382:microbiology* / Q000601:surgery; D006801:Humans; D008297:Male; D011655:Pulmonary Embolism / Q000150:complications; D011743:Pyrimidines / Q000494:pharmacology / Q000627:therapeutic use; D018805:Sepsis; D014230:Triazoles / Q000494:pharmacology / Q000627:therapeutic use; D014261:Tricuspid Valve / Q000382:microbiology*; D065819:Voriconazole
D000935:Antifungal Agents; D011743:Pyrimidines; D014230:Triazoles; C068538:liposomal amphotericin B; D000666:Amphotericin B; D065819:Voriconazole